MedTrace Logo

Digital Cognition Study During Long-COVID

NCT06391970 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-04-30

No results posted yet for this study

Summary

The persistence of the COVID-19 disease symptoms, such as extreme fatigue, shortness of breath, cardiovascular complications, depression and anxiety, pain, brain fog, loss of taste/smell, headaches as well as loss of memory has been evoked in many studies. This project aims at approaching the persistent symptomatology on cognition, more than 1 year after the infection.

When we refer to cognition, we refer to everything associated with knowledge, that is, the accumulation of information we have acquired through learning or from our experience. We can define cognitive processes as the processes we use to incorporate new knowledge and make decisions based on it. Through these processes several cognitive functions intervene: perception, attention, memory, reasoning, language, learning, decision-making. All of these cognitive functions work together to integrate knowledge as a whole and create an interpretation of the world around us. Usually neuropsychological tests are used to evaluate cognitive problems, they consist in different exercises sometimes with words, figures to draw, images to remember, movement to repeat, numbers to link together etc.

The DigiCog project here propose

1. to test and validate a very novel device, which uses the eyes movement during tasks to evaluate very quickly the cognitive functioning;
2. to study potential cognitive problems long-term after COVID-19; and
3. to explore how cognition could be preserved.

Finally, this project will also help to bring the innovative device tested to the market, for accurately monitoring people with long COVID.

Conditions

  • COVID-19, Long Haul

Interventions

DEVICE

Cognitive screening

The cognitive abilities of participants will be assessed using two different interventions: the first utilizing the new digital device, and the second employing the gold standard method.

Sponsors & Collaborators

  • ViewMind

    collaborator INDUSTRY

  • Luxembourg Institute of Health

    lead OTHER_GOV

Principal Investigators

  • Magali PERQUIN, PhD · Luxembourg Institute of Health

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-15
Primary Completion
2024-08-01
Completion
2025-09-30

Countries

  • Luxembourg

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06391970 on ClinicalTrials.gov